Your session is about to expire
← Back to Search
Gemcitabine/Nab-paclitaxel + Radiation Therapy + Surgical Resection for Pancreatic Cancer
Study Summary
This trial is testing a new combination of drugs and radiation therapy to treat pancreatic cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2012 Phase 3 trial • 256 Patients • NCT01005680Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Involvement of the aorta.You have HIV, HBV, or HCV.The vessel needs to be a certain length to be suitable.Two major arteries are affected.You have a blockage in the main vein of the liver that cannot be fixed.Your veins are affected a lot, but your arteries are not affected.You have a history of heart problems.You have had an organ transplant, heart problems, severe stomach issues, or nerve problems.Taking the medication coumadin for medical treatment.You have not had surgery to remove the tumor before.Cancer has spread to other parts of the body.You have had other types of cancer, but it has been at least 3 years since you completed treatment and have shown no signs of the disease.You have received radiation therapy or chemotherapy to the pancreas within the past year.You have moderate or severe existing nerve problems in your arms or legs.You have trouble breathing.The tumor can be removed with surgery according to current medical guidelines.You are able to perform daily activities without help or needing to rest most of the time.You have pancreatic cancer.You can use heparin for medical treatment.Your condition has gotten worse while on treatment before surgery.You have had a bone marrow transplant or stem cell rescue.You are younger than 70 years old.Your bone marrow and organs must be working well.You have been diagnosed with another type of cancer at the same time.There are no signs of the cancer spreading to other parts of the body.Your artery problem involves only one big blood vessel and can be surgically removed.It is possible to completely remove the tumor during surgery.You have kidney problems.
- Group 1: Gemcitabine/Nab-paclitaxel, Radiation and Surgery
- Approved for 10 Other Conditions - This treatment demonstrated efficacy for 10 other conditions.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Does this clinical research currently need new participants?
"This medical trial is no longer accepting patients. It was initially posted in July 2016 and had its last update on April 2021. If you are seeking alternative studies, there are 697 trials recruiting for malignant neoplasm of pancreas and 1112 clinical tests admitting participants that use Gemcitabine as an intervention."
How many individuals have enrolled in the trial to date?
"Unfortunately, this clinical trial is not presently admitting patients. Its first listing was July 1st 2016 with the last edit on April 14th 2021. Thankfully, for those seeking alternative studies there are 697 malignant neoplasm of pancreas and 1112 Gemcitabine trials actively enrolling participants at present."
Are there any extant studies exploring the efficacy of Gemcitabine?
"Currently, 1112 experiments are being conducted to investigate gemcitabine. Out of those trials, 321 have reached phase 3 and thus far the most common location for these studies is Shanghai however there are 59388 sites running tests on this medication."
Is the age requirement for participation in this clinical trial higher than 40 years old?
"As per the study guidelines, participants must be at least 18 years of age and no older than 70."
For which conditions is Gemcitabine a recommended treatment option?
"For the purpose of managing neoplasm metastasis, Gemcitabine is a common choice. This medication has also proven to be effective for locally advanced non-small cell lung cancer, metastatic bladder cancer, and urinary bladder issues."
Is my profile compatible with the qualifications for joining this research endeavor?
"This research endeavour is seeking 30 individuals aged 18-70 with a malignant neoplasm of the pancreas. Other conditions that must be met include no prior resection, absence of metastases, ability to obtain tumour free margins, acceptable vessel length, mass considered operable according to current standards, less than 70 years old and performance status <=2."
Share this study with friends
Copy Link
Messenger